title: Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Alessandra
authors.initials: A
authors.lastname: Serrao
authors.forename: Adriano
authors.initials: A
authors.lastname: Salaroli
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Loglisci
authors.forename: Irene
authors.initials: I
authors.lastname: Zacheo
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001752:Blast Crisis / Q000188:drug therapy*; D000069439:Dasatinib; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011743:Pyrimidines; D013844:Thiazoles; D014750:Vincristine; D000069439:Dasatinib